Yousif Capital Management LLC Sells Shares of Jazz Pharmaceuticals plc.
February 5, 2023
Trending News ☀️
Yousif Capital Management LLC recently announced that it has sold its shares of Jazz Pharmaceuticals ($NASDAQ:JAZZ) plc. The company focuses on developing drugs for the treatment of insomnia, narcolepsy, attention deficit hyperactivity disorder (ADHD), depression, bipolar disorder and other neurological disorders. Jazz Pharmaceuticals’ portfolio of products includes Xyrem®, Erwinaze®, Defitelio®, Prialt® and Vyxeos®. It also has a pipeline of experimental drugs in various stages of development. This enabled the company to further expand its portfolio of products and further strengthen its financial position.
Yousif Capital Management’s sale of its shares of Jazz Pharmaceuticals plc is part of its strategic move to focus more on other investments. The company has a strong financial position, a broad portfolio of products and an innovative pipeline of drugs in development. These factors present investors with an attractive opportunity to invest in Jazz Pharmaceuticals plc.
Market Price
The news of the sale has mostly been positive, although on Monday the stock opened at $156.3 and closed at $153.8, a decrease of 1.2% from its previous closing price of $155.6. JAZZ PHARMACEUTICALS specializes in developing treatments for rare and orphan diseases, as well as other areas of unmet medical need. Its products are marketed in countries across the world and it has a large portfolio of medicines and products in various stages of development. The company has a strong presence in the United States and Europe, and is continuing to expand its operations globally. Recently, it announced the opening of its new European headquarters in Dublin, Ireland. This move will help the company to further strengthen its presence in Europe and expand its access to new markets.
JAZZ PHARMACEUTICALS has also been actively pursuing strategic collaborations with other companies in order to develop new treatments and products. It has signed numerous agreements with leading pharmaceutical companies, such as Pfizer and GlaxoSmithKline, in order to develop products that can help improve patient outcomes. Despite the slight dip in stock prices on Monday, analysts remain optimistic about the company’s future prospects. With its strong presence in the United States and Europe, as well as its strategic collaborations with other pharmaceutical companies, Jazz Pharmaceuticals plc is well-positioned for growth in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Jazz Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 3.58k | -18.69 | 3.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Jazz Pharmaceuticals. More…
| Operations | Investing | Financing |
| 1.11k | -131.94 | -795.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Jazz Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 10.38k | 7.64k | 43.65 |
Key Ratios Snapshot
Some of the financial key ratios for Jazz Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.3% | -16.3% | 6.3% |
| FCF Margin | ROE | ROA |
| 27.5% | 4.7% | 1.4% |
Analysis
JAZZ PHARMACEUTICALS is a high risk investment for those considering it. GoodWhale has found five risk warnings in the income sheet, balance sheet, cashflow statement, non-financial, and financial journal. These risks are related to the financial and business aspects of JAZZ PHARMACEUTICALS. GoodWhale’s analysis considers a wide range of factors and data points to give investors an accurate assessment of the company’s risk level. This allows investors to make informed decisions about investing in JAZZ PHARMACEUTICALS. The analysis also looks at the company’s financial health and performance over time, as well as industry trends and potential future growth opportunities. GoodWhale’s risk rating is based on a comprehensive analysis of JAZZ PHARMACEUTICALS’ financial performance, including income statements, balance sheets, cashflow statements, non-financial information, and financial journals. The analysis is conducted using a variety of methods and tools, including machine learning and artificial intelligence. Investors should do their own research and analysis before investing in any company. GoodWhale’s risk rating is only a guide, and should not be taken as an investment recommendation. However, it can provide valuable insight into the potential risks associated with investing in JAZZ PHARMACEUTICALS. By utilizing GoodWhale’s analysis and risk ratings, investors can make informed decisions about investing in JAZZ PHARMACEUTICALS. With this data, investors can make better-informed decisions about their investments and better manage their portfolios. More…
Peers
The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.
– Nurix Therapeutics Inc ($NASDAQ:NRIX)
Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.
– Poxel SA ($LTS:0RA2)
Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.
Summary
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on the development, acquisition and commercialization of innovative treatments for underserved patient populations. Investors should consider the company’s strong financial performance and product portfolio, which has produced significant growth in revenue and earnings over the past several years. Furthermore, its product pipeline is promising with numerous late-stage clinical programs that could drive further growth in the future.
Jazz Pharmaceuticals has also recently announced a number of strategic partnerships and collaborations with other leading companies in the pharma space, which could unlock additional opportunities to expand its product portfolio. With these factors in mind, Jazz Pharmaceuticals appears to be a strong investment choice for those looking to gain exposure to the biopharmaceutical industry.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
